Search | IOVS | ARVO Journals

Showing 1 – 20 of 39

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2017

Long-term Outcome of Bevacizumab Therapy in Sorsby Fundus Dystrophy, A Case Series.

Rebecca Kaye; Andrew J Lotery

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):229. doi: https://doi.org/

ARVO Annual Meeting Abstract June 2017

UK Multi-centre Medisoft EMR audit of intra-operative pressure event following implant of ILUVIEN ® (fluocinolone acetonide 190 μg).

Fahd Quhill; Clare Bailey; Usha Chakravarthy; Andrew J Lotery; Geeta Menon; James Talks

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):4622. doi: https://doi.org/

ARVO Annual Meeting Abstract June 2017

The impact of prior steroid therapy on safety outcomes following treatment with ILUVIEN (fluocinolone acetonide) – An analysis of intra-ocular outcomes (IOP) from UK electronic medical records.

Serena Salvatore; Clare Bailey; Usha Chakravarthy; Andrew J Lotery; Geeta Menon; James Talks

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):4631. doi: https://doi.org/

ARVO Annual Meeting Abstract June 2017

Twelve-Month Outcomes of Aflibercept vs. Ranibizumab for Wet Macular Degeneration

Hussein Almuhtaseb; Luke Michaels; Thanos Vardarinos; Andrew J Lotery

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):431. doi: https://doi.org/

ARVO Annual Meeting Abstract June 2017

Twenty Four-Month Outcomes of Aflibercept for Neovascular Age-Related Macular Degeneration: Different Treatment Regimens in Year Two based on the Macular Status at the End of Year One

Luke Michaels; Hussein Almuhtaseb; Adham Youssef; Christina A Rennie; Andrew J Lotery

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):433. doi: https://doi.org/

ARVO Annual Meeting Abstract June 2017

Identification of a Novel Variant Associated with anti-VEGF Response in Age-related Macular Degeneration Using Exome Chip Analysis

Michelle Grunin; Laura Lorés-Motta; Moeen Riaz; Jordi Corominas; Andrea J. Richardson; Sascha Fauser; Robyn H Guymer; Eiko de Jong; Iris M Heid; Carel C B Hoyng; Andrew J Lotery; Paul Mitchell; Paul N Baird; Anneke I Den Hollander; Itay Chowers

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):1840. doi: https://doi.org/

ARVO Annual Meeting Abstract June 2017

The myocilin GLN368Stop mutation in normal tension glaucoma

Carly Lewis; Jason Kam; Todd E Scheetz; Ben R Roos; Edwin M Stone; Cheryl Khanna; Kazuhide Kawase; Robert Ritch; Andrew J Lotery; Sobha Sivaprasad; Jessica Cooke Bailey; Louis R Pasquale; Janey L. Wiggs; Young H Kwon; Wallace L M Alward; John Fingert

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):2127. doi: https://doi.org/

ARVO Annual Meeting Abstract June 2017

Hydroxyapatite induced experimental retinal degeneration in a murine model

Elena Pipi; Paul Ibbett; Andrew J Lotery; Imre Lengyel; V. Hugh Perry; Jessica Teeling

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):2272. doi: https://doi.org/

ARVO Annual Meeting Abstract June 2017

Murine Retinal Development, Morphology and Function in Albinism: Potential Implications for Therapeutic Development

Helena helenalee100@yahoo.co.uk Lee; Jennifer Scott; Helen Griffiths; Andrew J Lotery

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):5570. doi: https://doi.org/

ARVO Annual Meeting Abstract September 2016

Real-life outcomes of switching AntiVEGF treatment from ranibizumab to aflibercept for neovascular agerelated macular degeneration (nAMD): UK multicentre study.

Faruque Daudbhai Ghanchi; Nishal Patel; James S Talks; Andrew J Lotery; Sobha Sivaprasad; Clare Bailey; Rob Johnston; Martin McKibbin

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):3334. doi: https://doi.org/

ARVO Annual Meeting Abstract September 2016

A systematic review to assess the “Treat-and-Extend” dosing regimen compared to monthly and as-needed dosing for neovascular age-related macular degeneration using ranibizumab

Sohaib Riyaz Rufai; Hussein Almuhtaseb; Helena Lee; Richard Paul; Beth Stuart; Tony Kendrick; Andrew J Lotery

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):3367. doi: https://doi.org/

ARVO Annual Meeting Abstract September 2016

A novel biosynthetic RPE-BrM (Retinal Pigment Epithelium-Bruch's Membrane) assembly suitable for retinal transplantation therapy

Andrew J Lotery; Gareth Ward; Philip Alexander; David Johnston; Anton Page; Angela Jane Cree; Atul Bhaskar; Sumeet Mahajan; Martin Grossel; J Arjuna Ratnayaka

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12) doi: https://doi.org/

ARVO Annual Meeting Abstract September 2016

Spectral domain optical coherence tomography measurement of the retinal pigment epithelium and Bruch's membrane complex thickness, and its associations in a large population cohort, UK Biobank

Zaynah Ameerah Muthy; Fang Ko; Paul J Foster; Nicholas G Strouthidis; Qi Yang; Charles A Reisman; Usha Chakravarthy; Andrew J Lotery; Adnan Tufail; Pearse Andrew Keane; Praveen J Patel

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):4267. doi: https://doi.org/

ARVO Annual Meeting Abstract September 2016

A mouse model to study Aβ-driven pathology in the ageing retina.

Savannah Amy Lynn; Srini Goverdhan; Rosie Munday; Jennifer Scott; Thomas Freeman; David Johnston; Andrew J Lotery; J Arjuna Ratnayaka

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):6534. doi: https://doi.org/

ARVO Annual Meeting Abstract September 2016

One year visual and anatomic outcomes in eyes receiving aflibercept according to a fixed-interval dosing (Q8W) for neovascular age-related macular degeneration.

Osama Kanavati; Hussein Almuhtaseb; Georgios I Agorogiannis; Srini Goverdhan; Andrew J Lotery

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):517. doi: https://doi.org/

ARVO Annual Meeting Abstract September 2016

2nd Year Visual Acuity Outcomes of AMD patients treated with Aflibercept : Data Analysis from the UK Aflibercept users group

Hussein Almuhtaseb; James S Talks; Rob Johnston; Andrew J Lotery

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):545. doi: https://doi.org/

ARVO Annual Meeting Abstract September 2016

Long term vision results following retinal gene therapy for choroideremia

Robert E MacLaren; Thomas L Edwards; Jasleen Jolly; Alun R Barnard; Kanmin Xue; Susan Downes; Graham E Holder; Graeme C.M. Black; Andrew J Lotery; Andrew Webster; Miguel Seabra

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12) doi: https://doi.org/

ARVO Annual Meeting Abstract June 2015

Neural Potential of Human Limbal Cells

Xiaoli Chen; Pawez Hossain; Helen Griffiths; Jennifer Scott; Andrew J Lotery

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):3574. doi: https://doi.org/

ARVO Annual Meeting Abstract June 2015

Long term follow up of Sorsby fundus dystrophy patients treated with intravitreal bevacizumab

Hussein Almuhtaseb; Suman Pilli; Andrew J Lotery

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):3839. doi: https://doi.org/

ARVO Annual Meeting Abstract June 2015

The impact of systemic inflammation on age-related macular degeneration

Paul Luke Ibbett; Andrew J Lotery; V. Hugh Perry; Jessica Teeling

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):848. doi: https://doi.org/

1 2

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Long-term Outcome of Bevacizumab Therapy in Sorsby Fundus Dystrophy, A Case Series.

UK Multi-centre Medisoft EMR audit of intra-operative pressure event following implant of ILUVIEN ® (fluocinolone acetonide 190 μg).

The impact of prior steroid therapy on safety outcomes following treatment with ILUVIEN (fluocinolone acetonide) – An analysis of intra-ocular outcomes (IOP) from UK electronic medical records.

Twelve-Month Outcomes of Aflibercept vs. Ranibizumab for Wet Macular Degeneration

Twenty Four-Month Outcomes of Aflibercept for Neovascular Age-Related Macular Degeneration: Different Treatment Regimens in Year Two based on the Macular Status at the End of Year One

Identification of a Novel Variant Associated with anti-VEGF Response in Age-related Macular Degeneration Using Exome Chip Analysis

The myocilin GLN368Stop mutation in normal tension glaucoma

Hydroxyapatite induced experimental retinal degeneration in a murine model

Murine Retinal Development, Morphology and Function in Albinism: Potential Implications for Therapeutic Development

Real-life outcomes of switching AntiVEGF treatment from ranibizumab to aflibercept for neovascular agerelated macular degeneration (nAMD): UK multicentre study.

A systematic review to assess the “Treat-and-Extend” dosing regimen compared to monthly and as-needed dosing for neovascular age-related macular degeneration using ranibizumab

A novel biosynthetic RPE-BrM (Retinal Pigment Epithelium-Bruch's Membrane) assembly suitable for retinal transplantation therapy

Spectral domain optical coherence tomography measurement of the retinal pigment epithelium and Bruch's membrane complex thickness, and its associations in a large population cohort, UK Biobank

A mouse model to study Aβ-driven pathology in the ageing retina.

One year visual and anatomic outcomes in eyes receiving aflibercept according to a fixed-interval dosing (Q8W) for neovascular age-related macular degeneration.

2nd Year Visual Acuity Outcomes of AMD patients treated with Aflibercept : Data Analysis from the UK Aflibercept users group

Long term vision results following retinal gene therapy for choroideremia

Neural Potential of Human Limbal Cells

Long term follow up of Sorsby fundus dystrophy patients treated with intravitreal bevacizumab

The impact of systemic inflammation on age-related macular degeneration

To View More...

You must be signed into an individual account to use this feature.